MDGL Q1 2025 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$137M

Gross Profit

$133M96.7% margin

Operating Income

-$79M-57.8% margin

Net Income

-$73M-53.4% margin

EPS (Diluted)

$-3.32

QoQ Revenue Growth

+32.8%

Cash Flow

Operating Cash Flow

-$89M

Free Cash Flow

-$89M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$997M

Total Liabilities

$286M

Stockholders' Equity

$711M

Cash & Equivalents

$184M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$137M	$0	—
Gross Profit	$133M	$0	—
Operating Income	-$79M	-$152M	+47.8%
Net Income	-$73M	-$148M	+50.4%